Should antibiotic combinations be used to treat ventilator-associated pneumonia?

被引:12
作者
Eggimann, Philippe [1 ]
Revelly, Jean-Pierre [1 ]
机构
[1] CHU Vaudois, Surg Intens Care & Burn Unit, Dept Surg & Anesthesiol, CH-1011 Lausanne, Switzerland
关键词
ventilator-associated pneumonia; monotherapy; combined therapy; guidelines; synergy; multidrug resistance;
D O I
10.1055/s-2006-933675
中图分类号
R4 [临床医学];
学科分类号
1002 [临床医学]; 100602 [中西医结合临床];
摘要
This review summarizes the rationale for using or not using combinations of antibiotics to treat ventilator-associated pneumonia (VAP). Patients suffering from VAP require empirical antibiotic treatment before the identification of an etiologic agent. Most treatment failures are related to inappropriate initial antibiotic treatment with insufficient coverage of multidrug-resistant (MDR) pathogens. Guidelines require initial (empirical) treatment of VAP with a combination of antibiotics. However, this contributes to overexposure to antibiotics and further emergence of MDR microorganisms. We review the rationale for using combinations of antibiotics to cover MDR gram-negatives. However, clinical data supporting this strategy are limited. In fact, systematic combination therapy may have contributed to the overuse of antibiotics and to the emergence of MDR microorganisms. Nevertheless, combination therapy is our best strategy to treat severe infections due to suspected MDR microorganisms. Optimally, therapeutic strategies should be sufficiently broad to cover relevant pathogens while minimizing the risk for emergence of antimicrobial resistance.
引用
收藏
页码:68 / 81
页数:14
相关论文
共 140 条
[1]
Antibiotic synergy and antagonism [J].
Acar, JF .
MEDICAL CLINICS OF NORTH AMERICA, 2000, 84 (06) :1391-+
[2]
Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit [J].
AlvarezLerma, F ;
Pellus, AM ;
Sanchez, BA ;
Ortiz, EP ;
Jorda, R ;
Barcenilla, F ;
Maravi, E ;
Galvan, B ;
Palomar, M ;
Serra, J ;
Bermejo, B ;
Mateu, A ;
Quintana, E ;
Palacios, MS ;
Giral, R ;
Gonzalez, V ;
Lerma, FA ;
Mesa, JL ;
Melgarejo, JA ;
Martinez, J ;
Insausti, J ;
Olaechea, P ;
Chanovas, M ;
Gilabert, A ;
Junquera, C ;
Valles, J ;
Palacios, F ;
Calvo, R ;
Mesalles, E ;
Nava, J ;
Santos, A ;
Armengol, S ;
Marzo, D .
INTENSIVE CARE MEDICINE, 1996, 22 (05) :387-394
[3]
Baddour LM, 2005, CIRCULATION, V111, pE394, DOI 10.1161/CIRCULATIONAHA.105.165564
[4]
Pneumonia in intubated trauma patients - Microbiology and outcomes [J].
Baker, AM ;
Meredith, JW ;
Haponik, EF .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1996, 153 (01) :343-349
[5]
CEFEPIME VERSUS CEFOTAXIME IN THE TREATMENT OF LOWER RESPIRATORY-TRACT INFECTIONS [J].
BARCKOW, D ;
SCHWIGON, CD .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1993, 32 :187-193
[6]
Pharmacokinetic dosing of aminoglycosides: A controlled trial [J].
Bartal, C ;
Danon, A ;
Schlaeffer, F ;
Reisenberg, K ;
Alkan, M ;
Smoliakov, R ;
Sidi, A ;
Almog, Y .
AMERICAN JOURNAL OF MEDICINE, 2003, 114 (03) :194-198
[7]
Barza M, 1996, BRIT MED J, V312, P338
[8]
Mortality rate attributable to ventilator-associated nosocomial pneumonia in an adult intensive care unit: A prospective case-control study [J].
Bercault, N ;
Boulain, T .
CRITICAL CARE MEDICINE, 2001, 29 (12) :2303-2309
[9]
Pharmacokinetic/pharmacodynamic assessment of the in-vivo efficacy of imipenem alone or in combination with amikacin for the treatment of experimental multiresistant Acinetobacter baumannii pneumonia [J].
Bernabeu-Wittel, M ;
Pichardo, C ;
García-Curiel, A ;
Pachón-Ibáñez, ME ;
Ibáñez-Martínez, J ;
Jiménez-Mejías, ME ;
Pachón, J .
CLINICAL MICROBIOLOGY AND INFECTION, 2005, 11 (04) :319-325
[10]
Bochud Pierre-Yves, 2004, Crit Care Med, V32, pS495, DOI 10.1097/01.CCM.0000143118.41100.14